Company Page
Stipple Bio
Founders
Stipple Bio is a private precision oncology biotechnology company headquartered in Cambridge, MA. Founded by cancer biology pioneers Dr. Aaron Ring and Dr. Aashish Manglik, the company leverages its proprietary Pointillist Platform to identify tumor-specific cell surface epitopes at epitope-level resolution, enabling the development of highly targeted cancer therapies. Its lead candidate, STP-100, is a novel Antibody Drug Conjugate (ADC) designed to avoid on-target/off-tumor toxicity, with early-stage clinical trials planned for 2027.
Company Founded in 2022
